List of plasma metabolites after a single intake of 800 mg RJ capsules in human volunteersa.
| Metabolite | Putative formula | Metabolite putative identification | RT (min) | Assignation | Detected mass | Theoretical mass | Mass difference (ppm) | Ratio (vs. pre) | P (contribution) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 min | 1 h | 2 h | 4 h | 8 h | 12 h | 30 min | 1 h | 2 h | 4 h | 8 h | 12 h | ||||||||
| 1 | C5 H16 N8 O3 P2 | 11.34 | [M − H]− | 298.08156 | 298.08206 | −1.69 | 19.85 | 32.47 | 29.22 | 4.22 | 1.05 | 0.96 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 2.37 × 10−6 | 9.63 × 10−1 | 1.00 | |
| 2 | C6 H16 Cl N4 O3 P | 11.44 | [M − H]− | 258.06383 | 258.06485 | −3.99 | 17.51 | 28.09 | 14.91 | 3.04 | 1.09 | 1.04 | 1.75 × 10−9 | 1.00 × 10−15 | 1.00 × 10−15 | 8.71 × 10−2 | 1.00 | 1.00 | |
| 3 | C8 H10 N6 O2 | 11.43 | [M − H]− | 222.08666 | 222.08652 | 0.63 | 163.46 | 261.52 | 140.47 | 28.03 | 3.48 | 1.35 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 4.39 × 10−2 | 9.52 × 10−1 | |
| 4 | C9 H12 O | 2,4,6-Nonatrienalc | 11.42 | [M + H]+ | 136.08879 | 136.08881 | −0.18 | 37.39 | 64.97 | 42.09 | 7.21 | 1.45 | 1.23 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 3.23 × 10−7 | 9.89 × 10−1 | 1.00 |
| 5 | C9 H14 O2 | 2,4-Nonadienoic acidc | 11.41 | [M + H]+ | 154.09935 | 154.09938 | −0.19 | 9.37 | 14.75 | 10.45 | 1.89 | 0.89 | 0.64 | 5.86 × 10−6 | 7.93 × 10−11 | 7.63 × 10−10 | 5.20 × 10−1 | 1.00 | 9.94 × 10−1 |
| 6 | C9 H16 O2 | Nonane-4,6-dionec | 11.41 | [M − H]− | 156.11498 | 156.11503 | −0.29 | 53.12 | 87.00 | 71.66 | 11.88 | 1.87 | 1.08 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 1.20 × 10−1 | 1.00 |
| 7 | C9 H19 O3 P S | 11.37 | [M − H]− | 238.07870 | 238.07925 | −2.30 | 23.62 | 34.50 | 26.19 | 3.45 | 0.96 | 0.96 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 5.34 × 10−6 | 1.00 | 1.00 | |
| 8 | C10 H12 O2 | Eugenol;4-allylguaiacolc | 11.42 | [M + H]+ | 164.08376 | 164.08373 | 0.17 | 33.65 | 60.60 | 41.38 | 7.29 | 2.62 | 1.00 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 6.85 × 10−7 | 2.30 × 10−1 | 1.00 |
| 9 | C10 H14 O3 | 2-Oxo-delta-3-4,5,5-trimethylcyclopentenylacetatec | 11.41 | [M + H]+ | 182.09440 | 182.09429 | 0.58 | 31.16 | 51.13 | 38.11 | 6.38 | 1.25 | 1.15 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 6.41 × 10−6 | 1.00 | 1.00 |
| 10 | C10 H16 O4 | 2-Decenedioic acidb | 11.40 | [M − H]− | 200.10483 | 200.10486 | −0.16 | 58.53 | 95.50 | 77.06 | 14.00 | 2.69 | 1.46 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 7.78 × 10−3 | 8.77 × 10−1 |
| 11 | C10 H17 Cl O4 | 11.40 | [M − H]− | 236.08153 | 236.08154 | −0.03 | 53.45 | 88.57 | 77.16 | 11.49 | 2.40 | 0.92 | 1.00 × 10−15 | 1.00 × 10−15 | 1.00 × 10−15 | 1.23 × 10−9 | 8.62 × 10−1 | 9.73 × 10−1 | |
| 12 | C10 H18 O4 | Sebacic acidb | 11.85 | [M − H]− | 202.12047 | 202.12051 | −0.17 | 2.04 | 2.44 | 2.06 | 0.97 | 0.80 | 0.67 | 1.29 × 10−5 | 2.10 × 10−8 | 3.75 × 10−6 | 1.00 | 5.99 × 10−1 | 5.58 × 10−2 |
| 13 | C10 H18 O5 | 3-Hydroxysebacic acidb | 9.14 | [M − H]− | 218.11532 | 218.11542 | 2.18 | 2.84 | 5.23 | 4.03 | 1.43 | 0.81 | 0.99 | 1.34 × 10−5 | 1.00 × 10−15 | 1.91 × 10−10 | 3.60 × 10−1 | 9.98 × 10−1 | 9.99 × 10−1 |
| 14 | C10 H19 Cl O4 | 11.83 | [M − H]− | 238.09719 | 238.09719 | 0.01 | 2.12 | 2.18 | 1.98 | 1.07 | 0.92 | 0.81 | 1.44 × 10−6 | 5.55 × 10−7 | 6.60 × 10−6 | 9.95 × 10−1 | 9.34 × 10−1 | 9.33 × 10−1 | |
| 15 | C13 H14 O7 S | 11.34 | [M − H]− | 314.04524 | 314.04602 | −2.49 | 2.23 | 7.13 | 7.04 | 1.42 | 0.96 | 0.89 | 3.45 × 10−3 | 3.92 × 10−6 | 2.75 × 10−5 | 4.94 × 10−1 | 1.00 | 1.00 | |
| 16 | C14 H23 Cl O3 S2 | 11.35 | [M + H]+ | 338.07800 | 338.07771 | 0.85 | 6.42 | 19.15 | 18.87 | 1.31 | 1.04 | 1.02 | 3.05 × 10−6 | 3.12 × 10−10 | 4.10 × 10−9 | 1.72 × 10−1 | 1.00 | 1.00 | |
| 17 | C15 H10 N3 O2 P | 11.36 | [M + H]+ | 295.05107 | 295.05106 | 0.02 | 10.59 | 24.54 | 28.08 | 1.09 | 0.98 | 0.95 | 1.37 × 10−8 | 1.00 × 10−15 | 1.00 × 10−15 | 4.57 × 10−2 | 1.00 | 1.00 | |
| 18 | C18 H25 N5 O2 | 9.50 | [M + H]+ | 343.19916 | 343.20082 | −4.86 | 2.04 | 8.32 | 10.47 | 3.99 | 1.06 | 1.06 | 8.32 × 10−3 | 1.00 × 10−15 | 1.00 × 10−15 | 1.45 × 10−3 | 1.00 | 1.00 | |
| 19 | C18 H26 N6 O6 | 11.45 | [M − H]− | 422.19179 | 422.19138 | 0.97 | 28.17 | 67.82 | 28.74 | 1.24 | 1.11 | 0.98 | 2.20 × 10−6 | 6.83 × 10−11 | 1.14 × 10−10 | 9.33 × 10−1 | 1.00 | 1.00 | |
| 20 | C20 H32 O8 | 11.43 | [M − H]− | 400.20975 | 400.20972 | 0.08 | 31.54 | 95.29 | 52.04 | 1.63 | 1.11 | 0.98 | 6.29 × 10−7 | 1.00 × 10−15 | 1.00 × 10−15 | 8.00 × 10−1 | 1.00 | 1.00 | |
| 21 | C25 H40 O11 | Eriojaposide Bc | 11.44 | [M − H]− | 516.25697 | 516.25706 | −0.18 | 9.70 | 23.90 | 19.59 | 2.53 | 1.08 | 1.04 | 7.52 × 10−5 | 1.00 × 10−15 | 1.21 × 10−5 | 3.24 × 10−1 | 1.00 | 1.00 |
a
RT, retention time; [M − H]−, negatively charged molecular ion; [M + H]+, positively charged molecular ion. Mass difference was calculated by the subtraction of detected mass from theoretical mass. P values were comparing pre dose and after RJ ingestion (student's t test).
b
Identified using standard sample.
c
Putative identified on the basis of their exact mass (5 ppm of accepted mass difference) which was compared to that registered in databases.